Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DUPONT MERCK Tc-99m MARKER IS 90% ACCURATE IN DETECTING BREAST CANCER, STUDY SHOWS; SEPARATE TRIAL SUPPORTS ULTRASOUND AS ADJUNCT TO MAMMOGRAPHY

This article was originally published in The Gray Sheet

Executive Summary

Scintimammography performed with Dupont Merck's technecium-99m sestamibi nuclear marker can correctly identify more than 90% of cancers in women with "suspicious" tissue masses, Iraj Khalkhali, MD, University of California, Los Angeles, reported in a Nov. 28 press conference at the Radiological Society of North America's annual meeting in Chicago.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel